Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 14/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GCG | P01275 | 3/20 | 0.36 |
| ▸ | GIPR | P48546 | 3/20 | 0.36 |
| ▸ | GLP1R | P43220 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648396 | 0.88 | MAPK9 (0.48) | GCGRCYP2D6 | |
| SCHEMBL2665060 | 0.87 | GCGR (0.37) | DHODHGCGRCYP2D6EPHX2GCG | |
| SCHEMBL2653731 | 0.86 | HAO1 (0.46) | GCGRCYP2D6EPHX2PPARDHAO1 | |
| SCHEMBL2647806 | 0.85 | GCGR (0.44) | GCGRGCG | |
| SCHEMBL2660761 | 0.83 | GCGR (0.43) | DHODHGCGRCYP2D6GCGGIPR | |
| SCHEMBL2647399 | 0.82 | PPARD (0.47) | GCGRGCGGIPRGLP1RPPARD | |
| SCHEMBL2651641 | 0.82 | PPARD (0.47) | GCGRGCGGIPRGLP1RPPARD | |
| SCHEMBL2652188 | 0.82 | PPARD (0.47) | GCGRGCGGIPRGLP1RPPARD | |
| SCHEMBL2665081 | 0.82 | GCGR (0.49) | GCGRCYP2D6GIPRGLP1R | |
| SCHEMBL2647125 | 0.82 | CYP2D6 (0.45) | GCGRCYP2D6GCGGLP1RHAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | DHODH 4601/4885GCGR 4/4885CYP2D6 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.